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Abstract
Misperceptions surrounding the Bacille Calmette-Guerin (BCG) vaccine can lead some vaccinated 
individuals to resist being tested and treated for tuberculosis (TB). Educational messages to best 
explain the risk of TB to BCG-vaccinated, Hispanic persons were systematically developed and 
tested. First, TB program staff provided messages they considered effective. These were analyzed 
and validated by TB experts, and then presented in group interviews initially to foreign-born 
Hispanic persons with a TB diagnosis, and then persons without a prior TB diagnosis. Based on 
interviewees’ feedback, preferred statements were used to develop one long and three short 
comprehensive messages. One-on-one interviews were conducted with Hispanic persons to assess 
the saliency of the comprehensive educational messages. Participants preferred messages that were 
gain or positively-framed and explained that BCG does not confer lifelong protection against TB. 
Participants confirmed the messages would likely have a positive impact on patient decisions to 
undergo TB testing and treatment.
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Introduction
Tuberculosis (TB) remains a leading cause of morbidity and mortality worldwide. In many 
regions the disease is feared, the cause and route of transmission is poorly understood, and 
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diagnosed persons live in shame. The stigma and misperceptions surrounding TB have been 
associated with patients: (1) denying they can become ill; (2) delaying seeking care; (3) 
failing to undergo or complete diagnostic testing; (4) refusing treatment for latent 
tuberculosis infection (LTBI); and (4) failing to complete treatment for active TB disease [1–
8].
In 2011, foreign-born (FB) persons comprised 62 % of the 10,528 TB cases reported in the 
United States (US); 34 % of these cases were Hispanic or Latino [9]. Centers for disease 
control and prevention (CDC) surveillance data reveal that among the FB persons who 
develop active TB disease, approximately 31 % will do so within 4 years of their arrival in 
the US [9]. Thus, many immigrants become ill as they are becoming acculturated.
Research has demonstrated that when individuals are provided information that appears 
inconsistent with existing beliefs or behaviors, the resulting dissonance may lead some to 
purposefully avoid or ignore the new information [10]. Others may downplay the importance 
of the information, or add interpretations consistent with existing beliefs, behaviors, or 
personal characteristics [10]. These responses can lead people to develop a “biased 
optimism” that they will stay well despite their risks [11]. As such, healthcare providers are 
challenged to provide patient education in a manner that accommodates patients’ cultural 
understandings of disease, diminishes dissonance, and persuades these patients to follow 
medical recommendations [1, 2].
These challenges are compounded by the different approaches countries employ to control 
TB [2]. Countries such as the US and Canada test and treat people for LTBI, as well as those 
with active TB disease. In low to middle-income countries where TB is endemic, resources 
are primarily dedicated to treating those with active disease [2, 12]. These countries also 
vaccinate citizens against TB using the Bacille Calmette-Guérin (BCG) vaccine. Unlike 
vaccines in which one dose confers long-term protection, the protection offered by BCG is 
variable and incomplete [3–20].
Public health professionals regularly encounter reluctance or resistance to undergo TB 
testing and/or treatment among BCG-vaccinated persons. At times, this reluctance stems 
from erroneous beliefs that: (1) “positive” TB screening test results are solely caused by 
having been vaccinated with BCG, (2) BCG vaccine protects a person from becoming sick 
with TB throughout their entire life, and (3) if vaccinated, treatment for TB is not necessary 
[2, 21].
We report efforts to develop and characterize educational messages that would explain the 
risk of TB to BCG-vaccinated, foreign-born Hispanic persons, and mitigate the dissonance 
individuals experience relative to having undergone BCG vaccination and subsequently 
being informed they should be tested and treated for TB infection.
Methods
The project was executed in four phases. Prior to its initiation, the institutional review boards 
of the University of Florida and the Florida Department of Public Health reviewed and 
approved the protocol, recruitment materials, informed consent, and data collection forms.
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Based on the misperceptions surrounding the BCG vaccine, we recognized a broad 
educational message was needed to explain: (1) BCG has a protective effect, yet TB bacteria 
may still reside in the body of vaccinated persons in the form of a latent infection; (2) prior 
vaccination is not the sole reason a person’s tuberculin skin test or blood test is “positive”; 
and (3) TB bacteria can cause disease in vaccinated persons; accordingly, medication can be 
administered to prevent or cure TB disease. Thus, in Phase 1, TB program staff who work 
with a significant number of foreign-born patients, are recognized for their rapport with 
patients, and have a record of positive patient outcomes were identified and contacted. 
Project aims were explained and staff were asked to transcribe onto worksheets how they 
would explain why a belief is inaccurate, and persuade individuals who held inaccurate 
beliefs to get tested or treated for TB.
Submitted message statements were reviewed by TB experts to establish content validity. 
Messages were systematically analyzed and organized into seven thematic message 
statement groups. Statements were deleted if inaccurate or edited to improve reading ease. 
Investigators then selected statements most representative of each thematic group and strong 
from a theoretical perspective. Statements were translated from English to Spanish by two 
native Spanish speakers from Mexico, one of whom is a physician.
Phase 2 sought to discern the most persuasive statements in five of the seven thematic 
groups. Two semi-structured group interviews were conducted with six foreign-born 
Hispanic persons diagnosed with TB disease or latent TB infection. Participants were 
recruited through a State Tuberculosis Hospital and a County Health Department 
Tuberculosis Program, both in Florida. During group interviews, translated statements 
within each thematic group were presented using MS PowerPoint®. Participants’ message 
preferences were captured using an interactive audience response system. Mailed surveys 
combined with phone interviews were conducted with an additional four persons.
In Phase 3, four semi-structured focus group interviews were conducted with Hispanic 
persons who worked with, or sought services from, a community organization serving 
migrant workers. Persons were ineligible to participate if they had a prior diagnosis of active 
TB disease or had been treated for LTBI. Participants selected the statements they 
considered most persuasive in five of seven thematic groups, and discussed reasons for their 
choices. Statements were again presented using MS PowerPoint®. Participants were 
provided worksheets that mirrored the slides, and asked to mark preferred statements. 
Participants were also asked to share opinions of message content. Phase 3 participants were 
also shown phase 2 participants’ preferences and asked to comment on the phase 2 
participants’ choices Data from the worksheets were entered into an MS Access® database, 
exported to SPSS®, and analyzed. Phase 3 data were used to edit and combine statements 
from the thematic groups to create one long and three short comprehensive educational 
messages. Comprehensive messages were first created in English and then translated into 
Spanish.
Phase 4 aimed to assess the saliency of comprehensive educational messages with target 
audience members. One-on-one semi-structured interviews were conducted with eight 
Hispanic persons recruited through a community-based organization serving migrant 
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workers. None of the participants had a prior diagnosis of TB or LTBI. Participants were 
provided written copies of the four messages in Spanish. First, the long comprehensive 
message was read to the participant by the interviewer. Afterwards, participants were asked 
to report their thoughts as they listened to the message, explain the message in their own 
words, identify information that needed to be clarified, and share their opinions of the 
message’s persuasiveness. After each of the three short comprehensive messages was read, 
participants were asked to identify the short message they liked best, provide the rationale 
for their choice, and share their opinions of the selected message. After listening to all four 
comprehensive messages, participants were asked if they had any questions about the need 
for a BCG-vaccinated person to get tested or treated for TB. Interview responses from each 
participant were assembled into an MS Excel® Spreadsheet for comparison and analyzed.
All interviews in Phase 2 through 4 were conducted in Spanish, audiotaped, transcribed in 
Spanish, and translated into English.
Results
Table 1 provides a demographic profile of participants in each phase of this project.
Results: Phase 1
Staff from five state TB programs provided messages in Phase 1. A total of 32 responses 
were collected related to the misperception that a positive TB test is due to BCG. Thirty 
responses were collected related to the misperception of lifelong protection, and 32 
responses were collected related to treatment being unnecessary.
When message statements were reviewed to establish content validity, investigators and TB 
clinicians deleted statements that implied the vaccine’s protection was complete for a period 
of time. Statements that specified when the vaccine’s effect on skin testing subsided were 
also deleted, as the data do not support specific cut-points [22–25].
A review of message themes distinguished constructs from the Health Belief Model [26]; 
specifically: (1) perceived susceptibility of risk based on a person’s characteristics, (2) 
perceived severity of the consequences of TB, (3) perceived benefits of actions to take to 
reduce personal risk of TB and correct misinformation that can pose barriers to action.
This analysis also found some messages were positively-framed and sought to focus 
attention on the gains, protection, or positive consequences of a recommended course of 
action. Other messages were negatively-framed and drew attention to losses or negative 
consequences from not following the recommended course of action.
Moreover, some message statements reflected one of two routes by which people can be 
persuaded as per the Elaboration Likelihood Model [27, 28]. The central route to persuasion 
entails prompting an individual to draw upon experience and knowledge to evaluate an issue. 
(Example: “If the BCG vaccine provided lifetime protection, there would be very few cases 
of TB now.”) Whereas, the peripheral route occurs when an individual is unable or unwilling 
to contemplate an issue, and makes a decision based upon the source of information or the 
impact the information has on the individual’s affective state or attitudes [27, 28]. (Example: 
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“I know you care about yourself and your family. Do you really want to take the chance that 
you may have a disease that can kill you and spread it to your family and friends, as opposed 
to taking the treatment?”).
Finally investigators found similar message statements repeated across the three 
misperceptions. Accordingly, the message statements were consolidated into seven major 
thematic groups and subgroups (Table 2).
Messages statements that were representative of other statements in each thematic group and 
reflected various theoretical constructs were selected for presentation to participants in 
Phase 2 and 3. The decision was made to present statements from groups one to five (Table 
2) to participants since: (1) TB testing and treatment information is relatively 
straightforward, and (2) groups one through five contained 41 message statements, thus we 
sought to avoid perfunctory responses from fatigued participants [29].
Results: Phase 2 and 3
After reviewing the selected message statements, there was consensus among Phase 2 
participants that the messages in the five thematic groups had the capacity to garner people’s 
attention, enable understanding, and provide a clear rationale for TB testing and treatment, 
despite BCG vaccination.
Table 3 lists the English version of the message statements selected by Phase 3 participants 
as most salient in each thematic group. When asked why they preferred a particular 
statement, a few participants had difficulty articulating the specific reasons for their 
preferences beyond reiterating the statement in their own words, or declaring that their 
preferred statement “makes sense” or “explains more clearly.”
Additionally, some participants asked for information about how TB is transmitted, where to 
access TB testing, what TB testing entails, when and how often a person should be tested, 
TB symptoms, and whether allergies can cause a TB skin test to be mistakenly read as 
“positive”. Conversations revealed a few participants had undergone TB screening tests 
through their workplaces. While describing their experiences, it became evident some 
mistook the tuberculin skin test for a vaccination. Others, unaware of the bacterium’s 
capacity to establish a latent infection, expressed the belief that when they immigrated to the 
US, they had left the problem of TB behind. Many expressed appreciation for the knowledge 
acquired during the interviews.
Comprehensive Message Development
Multiple considerations were taken into account to develop the comprehensive messages 
tested in Phase 4; including message readability, the need to raise recipients’ perceived 
susceptibility to TB despite BCG vaccination, and perceived benefits of TB testing and LTBI 
treatment [30].
Message length was also contemplated. While Phase 2 and Phase 3 participants indicated an 
appreciation for descriptive information, putting information in context requires a longer 
message which may be overwhelming and dismissed as too complex. Conversely, shorter 
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messages with low literacy demands may not contain sufficient information to persuade 
recipients to initiate and complete multi-step diagnostic testing and lengthy treatment. Thus, 
both long and short messages were crafted and tested.
Message framing was a particularly significant consideration. Some studies have not found 
an advantage to using a particular frame to influence people’s judgment and behavior [31]. 
Others have concluded that negative or loss-framed messages are advantageous when an 
advocated behavior is detection-oriented (e.g., testing for active TB disease or LTBI) and 
prevention-oriented behaviors are better promoted by positive or gain-framed messages (e.g., 
treatment for LTBI to prevent progression to active TB disease) [31]. The decision was made 
to employ both positively- and negatively-framed information into a long comprehensive 
message (Message A), and to develop three short messages. Of these, “Message B” was 
primarily negatively-framed; “Message C” was primarily positively-framed; and “Message 
D” included both positively and negatively-framed statements.
Results: Phase 4
The English-language version of Message A, message readability calculations, and the 
concepts participants reiterated when asked are presented in Table 4.
When asked their thoughts after listening to the message, half the participants indicated they 
contemplated their own or family members’ susceptibility to TB. Others discussed increased 
perceptions of disease severity. The majority of participants were also able to clearly 
reiterate a number of the message’s concepts when asked to explain the statements in their 
own words. However, one participant’s response did display dissonance. After reiterating the 
benefit of the vaccine and “TB germs spread in the breath,” the participant included the 
belief that TB could be transmitted by sharing eating utensils.
When asked to identify information that needed clarification: one participant suggested 
defining “immature immune system,” another asked whether a person with LTBI could 
infect others, and two participants suggested including an explanation of how TB germs 
become airborne. One participant suggested the message explain who is at greater risk for 
becoming sick with TB disease.
When invited to state what they liked best about the message, participants indicated the: (1) 
explanation that the vaccine lowers a person’s chance of developing severe forms of TB if 
the germs are inhaled, (2) advice that a person not take a chance with their health, and (3) 
encouragement to take treatment to protect loved ones.
When asked whether the message would persuade a BCG-vaccinated person to undergo TB 
testing and treatment: six participants expressed favorable opinions, one participant specified 
it would depend on the person, and one participant was not asked the question.
Among the short messages three participants preferred Message C, one participant liked D 
but reported they better understood C, three liked Message D, and one preferred Message B.
Message C (Table 4) is primarily a gain/positively-framed message. Participants appreciated 
the assertion about the vaccine’s protection not lasting a lifetime is substantiated by the 
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statement that a significant amount of TB exists in countries that use BCG. Among the three 
participants who selected Message D (Table 4): two felt the message’s explanations were 
clearer, and one indicated the information regarding testing was more distinct.
Discussion
Tuberculosis continues to be a major cause of death and disability globally [32]. The 
development of improved tools for the diagnosis and treatment of TB is vital. Immunologic 
tests, new drugs, and improved vaccines are also needed. However the basic biomedical 
approach to controlling and eventually eliminating TB is insufficient. The myths and 
misconceptions that surround the etiology, transmission, diagnosis, and treatment of TB are 
among the most effective means for stigmatizing patients, eroding their self-esteem, and 
impoverishing patients and their families. Moreover, these mistaken beliefs and 
misunderstandings alter peoples’ behavior, engender secrecy, and can generate mistrust 
between patients and providers, all of which impede TB prevention and control efforts.
Generally, there is little guidance for framing patient education to accommodate cultural 
understandings of health and disease. Consequently, individuals who receive information 
that appears logically inconsistent with long-held beliefs and practices may experience 
dissonance, engage in avoidance behaviors, or modify misperceptions of their disease or 
condition so as to reconcile old information with new. This project attempted to address this 
issue by constructing and testing educational messages that address misperceptions 
surrounding the BCG vaccine. However our findings are limited; and as qualitative research, 
cannot be generalized.
The comprehensive educational messages were developed and evaluated with feedback from 
Hispanic persons only. Further testing is needed to ensure the messages are culturally 
appropriate for persons emigrating from countries in other regions that also use BCG. 
Additionally, evaluation is needed to ascertain whether these messages, or refined versions, 
have a positive impact on TB program indicators such as the rates people return to obtain TB 
test results, and initiation and completion of LTBI treatment. Evaluation efforts should 
assess birthplace, as persons from countries with a low TB burden or countries that do not 
employ BCG may not be persuaded to undergo testing using these messages.
In some jurisdictions, blood assays have replaced tuberculin skin tests (TST). While studies 
have found the sensitivity of the TST and some assays to be variable [33–35], patients may 
perceive a blood test as more credible, which could challenge some BCG misperceptions. 
This warrants further investigation.
Finally, the messages developed through this project are intended to assist TB program staff 
initially engage persons exposed to infectious cases in a dialogue, lessen initial hesitation to 
undergo screening tests or treatment, and actively listen to additional information. As such, 
they are not nuanced, nor do they address important issues such as: the probability of 
progressing from LTBI to TB disease; LTBI treatment adverse events; public health’s aim of 
reducing TB incidence through LTBI detection and treatment; or the right to decline 
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treatment for LTBI. Additional supplementary messages addressing these topics should be 
delivered based on an individual’s test results and risk factors.
Conclusions/Contribution to the Literature
Foreign-born, BCG-vaccinated Hispanic persons may be more likely to undergo diagnostic 
testing and treatment for LTBI when presented with positively-framed educational 
information that addresses the gains or protection garnered through these processes. Study 
participants, representative of this target audience, expressed preferences for messages that 
explain the protection from the vaccine wanes; encourage people to draw upon their 
knowledge of TB’s prevalence despite widespread use of the BCG vaccine; and focus 
attention on obtaining positive outcomes for the individual and loved ones. The messages 
developed and tested through this project warrant additional refinement, testing, and 
evaluation.
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Table 2
Message statement thematic groups and subgroups
Group Group labels and sub-group labels
1. In general, why BCG is given
 Where the vaccine is used
 Who is given the vaccine
 Why children are given the vaccine
2. BCG helps to decrease the risk of developing severe forms of TB
3. Why the vaccine is not completely effective/protection wanes
4. Evidence the vaccine’s protection wanes
 Incidence of TB around the world
 Testing outcomes
 The “Clinical Picture” (signs and symptoms of illness)
5. Reasons for getting tested for TB
 The vaccine
 Know your test results
 What you gain from being tested
 What you can lose from not being tested
6. The TB testing process and test results
7. Treatment
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Table 3
Educational information arranged by thematic group with messages statements selected as most salient by 
participants
Thematic groups and subgroups Message statements Participants who 
selected this statement 
(N = 43)
Group 1: “In general, why BCG is given”
 Introductory Statements: Where the vaccine is used 
and who are the recipients
BCG is used in countries where many people are sick 
with tuberculosis (TB). The vaccine is given to babies 
and small children.
N/A
 Participants were asked to select the best 2 of 4 
messages choices.
Because they can come into contact with persons with 
TB, and babies and small children have an immature 
immune system.
67.4 % (n = 29)
Many more babies would die in the world if the BCG 
was not administered.
55.8 % (n = 24)
Group 2: “BCG decreases the risk of developing severe forms of TB”
 Participants were asked to select the best 1 of 4 
messages choices.
BCG lowers the chance a person will develop severe 
forms of TB or die from TB, if they breathe in the TB 
germ.
37.2 % (n = 16)
Group 3: “The vaccine is not completely effective/protection wanes”
 Introductory statement:
Acknowledge seminal misperception
Many people think the BCG vaccine will protect them 
from TB for their entire life.
N/A
 The vaccine’s effectiveness The vaccine does not always prevent tuberculosis. 65.1 % (n = 28)
 Participants were asked to select the best 2 of 4 
messages choices.
Even with the BCG vaccine, you can still inhale the 
germ, and become infected.
62.8 % (n = 27)
 Protection wanes
Participants were asked to select the best 1 of 3 
messages choices.
Protection from the vaccination does not last your entire 
life.
51.2 % (n = 22)
 Summary statement: So, people who have had the BCG vaccine can still get 
sick with TB.
N/A
Group 4: “Evidence that the vaccination’s protection wanes”
 TB around the world/Global prevalence
Participants were asked to select the best 1 of 3 
messages choices
We still have a lot of TB disease in the world and mostly 
in the countries that do get BCG vaccine.
39.5 % (n = 17)
 Testing outcomes
Participants were asked to select the best 1 of 2 
messages choices
We have tested other people from your country who 
were given the vaccine; their tests were negative. This 
demonstrates that a (your) positive reaction is a result of 
exposure to a case, not from the BCG vaccine.
48.8 % (n = 21)
Group 5: “Reasons for getting tested/treated for TB”
 What you can lose from not being tested
Participants were asked to select the best 2 of 5 
messages choices
Do not take a chance with your health. If the tests show 
the TB germs are in your body, take the treatment, 
because TB can kill you. Without treatment, you can 
spread the TB germs to your family and friends.
79.1 % (n = 34)
I know you care about yourself and your family. 37.2 % (n = 16)
 The vaccine
Participants were asked to select the best 2 of 6 
messages choices
Because BCG vaccination does not last a lifetime, it is 
important to your health that you be tested and treated.
48.8 % (n = 21)
Knowing that the protection from BCG wears off, it is 
important to test to find out if the TB germs are in the 
body.
46.5 % (n = 20)
Even if you were given the BCG vaccine when you were 
a child, you can become sick with TB if you breathe in 
TB germs.
46.5 % (n = 20)
 Knowing your results
Participants were asked to select the best 2 of 4 
messages choices
“Knowledge is power,” and we can protect ourselves 
from certain diseases by getting tested/or receiving 
therapy.
46.5 % (n = 20)
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Thematic groups and subgroups Message statements Participants who 
selected this statement 
(N = 43)
The test is important. It will tell us if the TB germs are 
in your body and if you need medicine.
44.2 % (n = 19)
 What you gain from being tested
Participants were asked to select the best 2 of 6 
messages choices
If your tests show the germs are in your body, you need 
to be treated so you can be healthy and keep those you 
love safe from TB.
60.5 % (n = 26)
Being tested will help you know if you need the 
preventative treatment.
51.2 % (n = 22)
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Table 4
Developed messages, participant reiterated concepts, and readability statistics
Message Readability
Long message A
BCG is used in countries where many people are sick with tuberculosis (TB). Small children have an 
immature immune system. Because they may be exposed to persons with TB, the vaccine is given to 
babies and small children.
Many people think the BCG vaccine will protect them from TB for their entire life. However, the 
vaccine does not always prevent tuberculosis.
If a person breathes in TB germs, the vaccine helps lower the chance a person will develop severe forms 
of TB or die from TB. So, people who have had the BCG vaccine can still get sick with TB.
We have tested other people from your country who were given the vaccine; their tests were negative. 
This shows a positive test is probably the result of contact with a person sick with TB disease, and 
not from the vaccine.
Do not take a chance with your health. If the tests show the TB germs are in your body, take the 
treatment, because TB can kill you.
With no treatment, you can get sick and spread TB germs to your family and friends. Get treated, stay 
healthy, and keep those you love safe from TB
English version
Number of words: 195
Number of sentences: 13
Flesch Kincaid Grade level1: 6.66







We still have lot of TB disease in the world.
Most of the TB is found in countries that use the BCG vaccine.
If the vaccine protected a person for life, tuberculosis would not be a problem in the world.
“Knowledge is power,” and we can protect ourselves from disease.
Knowing the protection from the vaccine wears off, it is important to be tested for TB.
If your tests show TB germs are in your body, you need to be treated.
Treatment will help you stay healthy and keep those you love safe from TB.
English version
Number of words: 96
Number of sentences: 7
Flesch Kincaid Grade level1: 5.86







Many people think the BCG vaccine will protect them from TB for their entire life.
If the BCG vaccine protected a person for life, TB would not be a problem in the world.
People who have had the BCG vaccine can still get sick with TB.
“Knowledge is power,” and we can protect ourselves from disease.
Knowing the protection from the BCG vaccine wears off, it is important to be tested for TB.
Find out if TB germs are in your body, and if you need medicine.
If your tests show TB germs are in your body, you need to be treated.
Treatment will help you stay healthy and keep those you love safe from TB
English version
Number of words: 116
Number of sentences: 8
Flesch Kincaid Grade level1: 5.75
Flesch Reading Ease2: 79.91 
(Fairly Easy)
Spanish version
Fernandez-Huerta Reading Ease3: 
97
(Very Easy)
Readability calculated with an online software tool:—http://www.online-utility.org/english/readability_test_and_improve.jsp When asked to 
explain the message in their own words, 50 % or more of participants reiterated the statements in bold font
1
Flesch Kincaid grade level: rates text on a US school grade level
2
The Flesch reading ease score: rates English text on a 100 point scale, a higher number indicates the document is easier to understand
3
Fernandez-Huerta reading ease: an adaptation of the Flesch reading ease score, the Fernandez-Huerta readability formula calculates the readability 
of text in Spanish
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